论文部分内容阅读
目的观察吉西他滨(GEM)联合奥沙利铂(OXA)治疗晚期非小细胞肺癌的近期疗效和副反应,并与GEM联合顺铂(DDP)方案比较。方法 63例患者按随机数字表法分为2组,A组32例应用GEM联合OXA,B组31例应用GEM联合DDP,均化疗2周期以上。结果 63例均可评价,A组完全缓解(CR)2例,部分缓解(PR)12例,有效率(RR)为43.75%(14/32),中位无进展生存期(PFS)为8.2个月;B组CR2例,PR11例,RR为41.94%(13/31),PFS为8.5个月。2组间疗效及PFS均无统计学差异(P均>0.05)。2组均无化疗相关性死亡;主要不良反应为胃肠反应和骨髓抑制、神经毒性、肾毒性,A组神经毒性较重,B组消化道反应及肾毒性较重,但发生率比较差异均无统计学意义(P均>0.05)。结论两种方案对晚期非小细胞肺癌患者均有较好疗效且疗效相当,副反应可以耐受。患者对GEM联合OXA方案耐受性更好。
Objective To observe the short-term efficacy and side effects of gemcitabine (GEM) combined with oxaliplatin (OXA) in the treatment of advanced non-small cell lung cancer (NSCLC) and to compare with GEM combined with cisplatin (DDP). Methods Sixty-three patients were divided into two groups according to the random number table: 32 cases in group A were treated with GEM plus OXA, and 31 cases in group B were treated with GEM combined with DDP. Results All 63 patients were eligible for evaluation. Group A achieved complete remission (CR) in 2 patients and partial remission (PR) in 12 patients. The effective rate was 43.75% (14/32) and the median progression - free survival (PFS) was 8.2 Month; Group B CR2 cases, PR11 cases, RR was 41.94% (13/31), PFS was 8.5 months. There was no significant difference between the two groups (P> 0.05). There were no chemotherapy-related deaths in the two groups. The main adverse reactions were gastrointestinal reaction and myelosuppression, neurotoxicity and nephrotoxicity, severe neurotoxicity in group A, severe digestive tract reaction and nephrotoxicity in group B, but the difference was statistically significant No statistical significance (P> 0.05). Conclusion Both of the two regimens have good curative effect and equivalent curative effect in patients with advanced non-small cell lung cancer, and the side effects can be tolerated. Patients are more tolerant of GEM plus OXA regimen.